Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
IR Contact
News
-
March 26, 2020Targovax to present at the 2020 Solebury Trout Virtual Investor Conference today
-
March 20, 2020Impact of corona virus (COVID-19) on Targovax’s operations
-
March 11, 2020Targovax ASA: Fourth quarter 2019 results
-
March 11, 2020Targovax ASA: Annual Report 2019